<![CDATA[Background: Omentin-1, a novel adipokine predominantly secreted by visceral adipose tissue, modulates glucose metabolism, inflammation, and carcinogenesis, yet its clinical significance in prostate cancer remains underexplored. Knowledge Gap: While adipokines are implicated in obesity-related malignancies, the specific relationship between serum omentin-1 levels and prostate cancer, particularly regarding body mass index and metabolic parameters, is not fully understood. Aims: This study evaluated serum omentin-1 concentrations in 88 newly diagnosed prostate cancer patients compared to 88 age-matched healthy controls, examining correlations with anthropometric measurements and biochemical markers. Results: Serum omentin-1 levels were significantly elevated in prostate cancer patients, particularly in younger age groups and normal-weight to overweight categories, with negative correlation to BMI (r=−0.3, p<0.01) and positive correlation to PSA (r=0.5, p<0.01); multivariate regression identified omentin-1 as an independent protective factor (OR=0.79, p<0.0001). Novelty: This research establishes omentin-1 as an independent predictor of prostate cancer risk alongside traditional biomarkers. Implications: These findings suggest omentin-1 may serve as a complementary biomarker reflecting metabolic-oncological interactions in prostate cancer risk stratification.Keywords : Omentin-1, Prostate Cancer, Body Mass Index, Prostate-Specific Antigen, AdipokinesHighlight : Omentin-1 levels negatively correlate with BMI but positively correlate with PSA levels. Elevated omentin-1 particularly evident in younger age groups and normal-weight individuals. Omentin-1 identified as independent protective factor against prostate cancer in regression analysis.]]>
